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Plasma Cell Leukemia (PCL) is a rare and aggressive form of plasma cell dyscrasia that can arise either de novo (primary plasma
cell leukemia) or evolve from previously diagnosed and treated multiple myeloma (secondary PCL). We highlight three clinical
cases with very different presentations as a reminder of this diagnosis. (e cases also highlight the diversity and variability that
cover a patient’s journey that is highly dependent on accessibility based on financial capability and social support. (e clinical
presentation is more aggressive due to the higher tumour burden and more proliferative tumor cells with cytopenias being
profound and more organomegaly. (e diagnosis is made based on at least 20% of total white blood cells being circulating plasma
cells with a peripheral blood absolute plasma cell count of at least 2×109/l. Treatment with novel agents followed by autologous
stem cell transplant in those who are transplant eligible leads to better outcomes.
1. Introduction
Plasma Cell Leukemia (PCL) is a rare and aggressive form of
plasma cell dyscrasia that can arise either de novo (primary
plasma cell leukemia) or evolve from previously diagnosed
and treated multiple myeloma (secondary PCL) [1]. (ese
are seen as distinct entities that vary in clinical presentation
and survival. Due to the rarity of this clinical entity, most of
the data are case reviews and retrospective studies. We
report 3 clinical cases recently managed and discuss briefly
the available data around this condition.
2. Case Discussions
2.1. Case 1. A 51-year-old female with no comorbidities was
diagnosed with primary plasma cell leukemia in July 2018 after
presenting with symptomatic anemia. She also reported head-
aches with no focal neurological deficits and had right lower
limb swelling not associated with trauma or skin lesions. On
physical examination, the only remarkable finding was pallor
and right calf swelling with no signs of cellulitis. A complete
blood count revealed a leucocytosis of 99,000/ul, normocytic
anemia of 7.9 g/dl, and thrombocytopenia of 68,000/ul. A
peripheral blood film revealed 79% plasma cells, and bone
marrow aspirate showed plasmacytosis of 89% with serum
protein electrophoresis having an M protein of 6 g/l. (e serum
creatinine was slightly elevated at 158umol/l, and calcium levels
were normal with an elevation of lactate dehydrogenase at
469U/l. A Doppler ultrasound of the right lower limb ruled out
deep venous thrombosis but found a fluid collection suspected to
be a hematoma.A fewdays into her first admission at the referral
hospital, she complained of worsening headaches with associ-
ated blurring of vision and vomiting. Computed Tomography
(CT) of the brain performed showed bilateral frontoparietal and
temporal region subacute subdural hematomas. She was
managed conservatively for the hematomas and prophylactic
low-molecular-weight heparin (enoxaparin) held.
Initial definitive treatment was commenced with cy-
clophosphamide, thalidomide, and dexamethasone based on
the available medications; she received 5 cycles. On reas-
sessment, there was clearance of peripheral blood plasma-
cytosis on the peripheral smear; however, bone marrow
biopsy had persistent bone marrow plasmacytosis of 90%
with immunohistochemistry stains being positive for
CD138, CD 20, MUM 1, and BCL 2 with negative CD56, as
shown in Figure 1.
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Her treatment regimen was changed to bortezomib,
lenalidomide, and dexamethasone with complete response
after 4 cycles, no M protein, and normal serum free light
chains with bone marrow biopsy with immunohistochemistry
showing a plasmacytosis of less than 5%. She proceeded to go
for autologous stem cell transplant out of country inMay 2019.
Evaluation at the transplant facility included a bone
marrow aspirate and trephine that revealed a plasmacytosis
of 2% with no peripheral blood plasma cells. Other blood
parameters such as total blood count and liver and kidney
tests were normal, and a PET CT showed extensive lytic
lesions. She received 2 more doses of bortezomib and
dexamethasone as she awaited pretransplant work up.
She was mobilized with plerixafor after unsuccessful
attempts with Granulocyte Colony-Stimulating Factor
(GCSF), and conditioning was withmelphalan at 200mg/m2
followed by infusion of stem cells 24 hours later. Her
posttransplant period was complicated by mucositis and
febrile neutropenia that responded well to broad-spectrum
antibiotics. She had minimal signs of engraftment syndrome
managed with steroids and achieved engraftment of white
cells and platelets by day 11. After normalization of counts
and full recovery, she was discharged back home to have
consolidation chemotherapy after 60days after transplant
(twice weekly bortezomib and dexamethasone with 21 days
of lenalidomide 10mg) and then proceed to maintenance
with lenalidomide and dexamethasone. (e patient did well
and remained in remission for 1 year.
2.2. Case 2. A 48-year-old male patient presented with gen-
eralized body weakness and unintentional weight loss with no
fever or bleeding diathesis. Upon admission, he was found to
have pallor but no palpable peripheral adenopathy or hep-
atosplenomegaly. A total blood count revealed a macrocytic
anemia (Hb 7.9 g/dl,MCV 106fl) with a leucocytosis of 36,290/
ul (neutrophils 26%, lymphocytes 20%, and monocytes 51%)
with a platelet count of 141,000/ul. Reticulocyte count was low
at 1% with normal serum B12 and folate levels. A peripheral
smear revealed anisocytosis, normochromic red cells, left shift
of white blood cells, and large mononuclear plasmacytoid cells
which were more than 20%. A diagnosis of plasma cell leu-
kemia was made after bone marrow aspiration that showed
infiltration with plasma cells and increase in small
mature lymphocytes; however, there was no trephine with
immunohistochemistry. In addition, flow cytometry on pe-
ripheral blood showed that the abnormal cell population
expressed CD38, CD138 and they were lambda restricted;
however, B- and T-cell markers were negative as well as CD56.
Serum protein electrophoresis showed an M band of 4.2 g/l, as
shown in Figure 2, with elevated lambda free light chains of
461mg/l. Serum immunofixation was not performed in this
case. CT scans of the chest and abdomen were unremarkable
with no adenopathy and normal-size spleen and liver. Serology
for HIV, hepatitis B, and hepatitis C was negative.
He was transfused during his first admission, discharged
home, but was readmitted one week later with worsening
generalized body weakness, dyspnea, and diarrhoea. He was
sick looking and markedly dehydrated with bilateral pitting
edema to the level of the knee but clear chest exam. He was
hypotensive with a blood pressure of 84/37mmHg with
hypoxia of 87% room air but afebrile at 36.7°C, and a diagnosis
of severe sepsis due to gastroenteritis was made and he
transferred from the emergency unit to the high-dependency
unit. His haemoglobin level was 11 g/dl given recent transfu-
sion but worsening of leucocytosis (60,000/ul) and thrombo-
cytopenia of 43,000/ul. He had acute kidney injury with low
total protein and serum albumin (Table 1 outlines a summary
of a few selected results during his hospital stay).
(e second admission was more protracted lasting 30
days with a predominant time being spent in the high-de-
pendency unit (HDU). Due to lack of blood pressure response
to fluid resuscitation, he was initiated on inotropic support.
Hypoalbuminemia resulted in third spacing of fluid, but this
improved with administration of intravenous albumin. Given





Figure 1: Representative micrograph of the bone marrow biopsy (a, b); original magnification ×20 haematoxylin eosin (H&E) stain shows a
diffuse infiltration by plasma cells with suppressed trilineage haematopoiesis. (ese plasma cells are positive for CD138 and negative for
CD56.
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platelet count, he received adjusted-dose chemotherapy: 1
gram of intravenous cyclophosphamide and weekly dexa-
methasone 40mg with bortezomib being held due to low
platelets. He tolerated his chemotherapy well. However, on
hospital day 10, he developed worsening respiratory symp-
toms with a new oxygen requirement, and chest radiograph
revealed features of pneumonia for which he was commenced
on broad-spectrum antibiotics with piperacillin-tazobactam.
Subsequently, on hospital day 15, he further desaturated with
clinical signs of a right-sided pleural effusion. (is was
hemorrhagic and drained with a pigtail catheter with the fluid
analysis showing an exudate, normal adenine deaminase
levels, negative Zielh Niessen stain, and no malignant cells on
cytology. (is was, therefore, managed as a parapneumonic
effusion and drain removed after having no more output. He
required transfusions whenever his haemoglobin dropped but
did not need platelet transfusion.
He slowly improved initially getting off inotropes,
weaning off oxygen successfully to the point of discharge
after 30 days in the hospital.
Two weeks after discharge, the patient was more stable
with good rehabilitation given prolonged hospitalization
that was associated with significant weight loss and reduced
level of activity. He was commenced on a bortezomib-based
regimen (bortezomib, lenalidomide, and dexamethasone)
and has achieved complete response with a plan for au-
tologous stem cell transplant to consolidate the response.
2.3. Case 3. A 53-year-old female referred with a 9-month
history of easy fatigability. She had associated bone pains,
predominantly back and knee pain, which were previously
managed as arthritis. She had no bleeding diathesis, hem-
atemesis, or melena. (ere was no known family history of
Table 1: Selected lab investigations during his hospital stay.
Investigations Baseline Day 4 Day 9 Day 13 Day 15 Day 16
Hemoglobin (g/dl) 11.3 9.9 9.3 11.6 12.9 12.3
White cell count 60.2 44.98 25.35 12.13 13.48 17.34
Platelet 43 36 31 76 86 161
Urea (1.5–8.5mmol/l) 8.95 6.97 5.41 3.88 4.09 3.6
Creatinine (40–133 umol/l) 154 148 80 58 53 60
K (3.5–5.5mmol/l) 4.15 4.25 3.48 3.23 3.8 4.18
T protein (60–83 gm/l) 39.8 41.9 46.8 57.3 53.8 —
Albumin (35–52 g/l) 24.27 27 27.6 43.56 37.8 —
ALT (0–41 u/l) 30.6 40.9 53.6 31.5 21 —
Total bilirubin(2–21 umol/l) 37 33 45 45 23 —
LDH (90–244 u/l) 1116 — — 738 — —
Uric acid (202–416 umol/l) 399 122 119 220
Calcium (2.02–2.6mmol/l) 2.2 — 2.2 — — —
Fractions % Ref. % g/dl Ref. g/dl
Albumin 63.1 55.8 – 66.1 2.52 3.97 – 4.95
Alpha 1 7.8 2.9 – 4.9 0.31 0.21 – 0.35
Alpha 2 7.4 7.1 – 11.8 0.30 0.51 – 0.85
Beta 1 3.5 4.7 – 7.2 0.14 0.34 – 0.52
Beta 2 3.2 3.2 – 6.5 0.13 0.23 – 0.47
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Figure 2: Serum protein electrophoresis showing an M protein of 4.2 g/l.
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malignancy or haematological condition, and she had no
history of tobacco use or exposure to chemicals and reported
no underlying comorbidities.
She presented to a health facility with palpitations and
worsening general body weakness. (ere, she was found to
have severe anemia (haemoglobin of 4.5 g/dl), thrombocy-
topenia, and acute kidney injury with high serum calcium
levels. Her record of actual values was not available. She was
transfused both packed red blood cells and pooled platelets.
In addition, she received intravenous fluids which resulted in
improvement of her renal function. Other laboratory in-
vestigations revealed normal serum folate and B12 levels,
elevated uric acid, and lactate dehydrogenase (LDH) and a
total protein of 100 gm/dl with a monoclonal protein of 54 g/
l. An abdominal ultrasound revealed splenomegaly but no
intra-abdominal adenopathy. A peripheral blood film
showed a leucoerythroblastic picture with atypical mono-
nuclear cells with plasmacytoid appearance at 45% and bone
marrow aspirate and trephine revealed infiltration with 74%
atypical plasmacytoid cells with a limited immunohisto-
chemistry stains being positive for CD38 and negative for
CD20, CD3, MUM1/IRF4, and Tdt.
Her initial treatment course comprised steroids and
allopurinol while receiving transfusions of blood products
and later was started on bortezomib, lenalidomide, and
dexamethasone. Bortezomib was held after a few treatments
due to low platelet counts and challenges of platelet
transfusions; she, therefore, continued with low-dose
lenalidomide and dexamethasone. Two months into her
treatment, she developed congestive heart failure with
preserved ejection fraction on echocardiography and
symptoms improved on diuretics. She had treatment in-
terruptions due to congestive hepatopathy resulting in
transaminitis, and medications were restarted when this
improved. She also continued to fluctuate in her transfusion
requirements which would be carried out at remote facilities
due to financial constraints. Initially, she did well; however,
during her third cycle, she was reported to have easy fati-
guability and shortness of breath and taken to a nearby
hospital for urgent care; however, she succumbed in a few
days.(e cause of death at this point was not clear given lack
of access to records from the admitting hospital.
(is case highlights the challenges that clinicians in sub-
Saharan Africa face in managing patients where cost affects
choices patients make in seeking care, especially with regard
to hospital admissions. As a result, in the clinical journey,
they receive part of care at a facility away from their primary
doctor, especially in-patient.
3. Epidemiology and Clinical Presentation
PCL is not common with various studies reporting incidence
of less than 1% to 4% [2–4]. (e median age is younger than
for MM patients, between 50 and 60 years with a slight male
predominance [5, 6]. Studies conducted in China revealed a
younger population below 50 years [7, 8]. Our patients were
all less than 60 years with the youngest being 48 years.
Unlike MM, patients with plasma cell leukemia have a
more aggressive clinical presentation due to a higher tumour
burden. (e symptoms may range from profound cytope-
nias, mainly anemia and thrombocytopenia resulting in
bleeding diathesis. (ey can also present with bone pain,
symptoms due to hypercalcemia, or acute kidney injury
[5, 9, 10].
On physical examination, these patients have a higher
prevalence of organomegaly with involvement of the liver
and spleen [11]. Other patients may have pleural effusion,
neurological deficits due to CNS involvement, or palpable
extramedullary soft tissue plasmacytomas. (is is reflected
by cases discussed.
Lytic lesions on imaging is reported to be lower than in
MM; however, it may be found in approximately half of the
patients more so those with sPCL [11]. (is is illustrated in
the first case where the patient had extensive lytic disease,
hence the question whether she had sPCL as opposed to
pPCL.
4. Diagnosis
Kyles’ criteria described in 1974 required at least 20% of total
white blood cells be circulating plasma cells with a peripheral
blood absolute plasma cell count of at least 2×109/l [12].
(ere is debate on whether both criteria need to be met as
per Kyle et al.’s recommendation, and many reports have
used the presence of at least one criteria, although there is no
consensus as to threshold for diagnosis, with the increasing
studies showing that patients with circulating plasma cells
between 5 and 20% had shorter median overall survival of
approximately 6 months, similar to those with >20% PCs.
Advances in flow cytometry have allowed for better
characterization and clonal assessment of plasma cell
population. Clonality is important to establish to rule out
reactive plasma cells in context of infection or inflammation
which are polyclonal or exclude other lymphoproliferative
diseases such as lymphoplasmacytic lymphoma [9]. (e
International Myeloma Working Group (IMWG) and the
World Health Organization (WHO) have accepted that
either one of the criteria is sufficient.
CD138 and CD38 are expressed in plasma cells in mul-
tiple myeloma and plasma cell leukemia. CD56, a neuronal
cell adhesion molecule, seems to be more prevalent in MM as
opposed to B-cell marker CD 20 which are more positive in
PCL. CD56 which facilitates interactions with the bone
marrowmicroenvironment and prevents circulation from the
bone marrow to the blood tends to be absent in PCL [13]. In
addition, there is lower expression of CD9, CD117, and HLA
DR.(ere is higher CD28 expression in secondary PCLwhich
correlates with a rise in plasma cell proliferation and disease
progression. Increased expression of CD27 has been associ-
ated with activation of the antiapoptotic pathway.(e IMWG
consensus on PCL is that measurement of immunopheno-
typic residual disease is needed when there is no evidence of
plasma cell infiltration on routine morphology evaluation.
A majority of patients will have markedly elevated serum
lactate dehydrogenase (LDH) levels and B2 macroglobulin
[1, 14].
Most patients with PCL tend to have hypodiploidy or
pseudodiploidy and high risk or complex cytogenetic
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abnormalities [5, 8, 15]. Majority of the PCL cases had
translocation involving the immunoglobulin heavy-chain
locus (IgH) on 14q32 such as t (11, 14), t (4; 14), and t (14;
16). TP53 inactivation, MYC translocations, and mutations
in K-RAS and N-RAS were among those documented with
PTEN deletion which cause Akt activation being more in
sPCL.
Imaging either by whole-body MRI or PET CT scan is
important to check for any extramedullary component [1].
5. Management
Management includes adequate supportive care as well as
definitive therapy that depends on the transplant eligi-
bility. Choice of regimen will depend on patient perfor-
mance status, existing comorbidities, and availability of
drugs, as well as the centres’ ability to administer the
regimen.
Supportive treatment includes, but is not limited to,
transfusions, treating hypercalcemia, renal insufficiency, and
infections. It is important to watch out for tumour lysis given
the high tumour burden in this patient population. (is
would require the managing team to monitor uric acid,
potassium, calcium, phosphorous, and creatinine levels at
the time of instituting definitive therapy.
Studies have shown that use of drug combinations in-
volving novel agents has better responses andmedian overall
survival than use of single agents or conventional chemo-
therapy [16]. (e use of novel agents (immunomodulators
and proteasome inhibitors) has been associated with a
higher response rate which is consolidated to an even deeper
response by autologous stem cell transplant resulting in
improved overall survival [17]. Some examples of regimes in
transplant candidates are VTD-PACE (bortezomib, thalid-
omide, dexamethasone, cisplatin, doxorubicin, cyclophos-
phamide, and etoposide), HyperCVAD-VTD
(hyperfractionated cyclophosphamide, vincristine, adria-
mycin, dexamethasone, bortezomib, thalidomide, and
dexamethasone), PAD (Bortezomib, Adriamycin, and
Dexamethasone), and VCD (bortezomib, cyclophospha-
mide, and dexamethasone). After transplant, it is highly
recommended that these patients receive consolidation
therapy with bortezomib-based combinations followed by
maintenance.
Nontransplant candidates also receive bortezomib-based
regimens so as to achieve a rapid response and improve
outcome. (ese include CyBorD (cyclophosphamide, bor-
tezomib, and dexamethasone), VTD (bortezomib, thalido-
mide, and dexamethasone), and MPV (melphalan,
bortezomib, and prednisone) among others [18].
Many studies have demonstrated the effectiveness of
bortezomib in clearing plasma cell leukemia, normalizing
platelet count, and better overall survival compared to
conventional therapies [13, 19, 20]. Musto et al. showed 92%
overall response with the use of bortezomib which was also
replicated by the Greek Myeloma group that looked at a
larger patient population [16, 19]. It is, therefore, important
that where patients have no contraindications, bortezomib-
based regimens be used.
Lenalidomide-based therapies have reported overall
responses of 60% with clear lack of benefit with thalidomide.
(e later should, therefore, be avoided as initial therapy and
especially as monotherapy [19, 21–23].
An Italian multicentre retrospective review of 128 PCL
patients showed that hematopoietic stem cell transplant
improves overall survival and duration of response by 69%
and 88%, respectively [6]. Results from the Center for In-
ternational Blood and Marrow Transplant Research showed
that autologous stem cell transplant is better than allogeneic
stem cell transplant due to higher nonrelapse mortality with
no benefit in overall survival [21]. (e current challenge is
the short duration of response as demonstrated by a large
cohort of 272 pPCL patients in the European Group for
Blood and Marrow Transplantation when compared to
myeloma [24]. Newer agents have also been used in plasma
cell leukemia such as carfilzomib, ixazomib, monoclonal
antibodies to CD38 such as daratumumab, and novel
therapies such as Bcl-2 inhibitor, venetoclax in those with
t(11; 14) [25, 26].
6. Prognosis
Plasma cell leukemia has a poor prognosis in comparison to
multiple myeloma [11, 14, 26]. In addition, the outcome for
sPCL is much worse and most studies report survival of few
months in comparison to pPCL [9, 12, 14, 27]. Talamo et al.
who studied the outcome of PCL in the era of novel agents
found a median survival of 21 months for pPCL in com-
parison to 4 months for sPCL which was statistically sig-
nificant (p � 0.015) [27].
(e Center for International Blood and Marrow
Transplant Research documented an overall survival of 51%
at 5 years after pPCL treatment had been consolidated with
autologous stem cell transplant [21].
Studies have demonstrated some factors such as age
more than 60 yrs, platelet count less than 100,000/ul, and
peripheral blood plasma cells more than 20% to be pre-
dictors of worse survival [17]. Others reported include poor
performance status (ECOG >2) and elevated serum LDH, as
well as B2 microglobulin and cytogenetics such as 17 p
deletion [7].
7. Conclusions
Plasma cell leukemia is a rare aggressive form of plasma cell
dysrasia that needs to be diagnosed early and managed
aggressively before patients get complications. Given poor
prognosis, it is important to use novel agents as part of the
induction regimen followed by autologous transplant in
those who are transplant eligible. Despite the improvement
in diagnostics and treatment, sub-Saharan Africa faces
challenges where the patients’ treatment journey depends on
what they are able to afford and accessibility to those
services.
Conflicts of Interest
(e authors declare no conflicts of interest.
Case Reports in Hematology 5
References
[1] M. T. Gundesen, T. Lund, H. E. H. Moeller, and
N. Abildgaard, “Plasma cell leukemia: definition, presenta-
tion, and treatment,” Current Oncology Reports, vol. 21, no. 1,
p. 8, 2019.
[2] G. Ramsingh, P. Mehan, J. Luo, R. Vij, and D. Morgensztern,
“Plasma cell leukemia: a SEER database analysis,” Journal of
Clinical Oncology, vol. 27, no. 15_suppl, p. 8605, 2009.
[3] M. Sant, C. Allemani, C. Tereanu et al., “Incidence of he-
matologic malignancies in Europe by morphologic subtype:
results of the HAEMACARE project,” Blood, vol. 116, no. 19,
pp. 3724–3734, 2010.
[4] P. Gimsing, M. Holmstrøm, T. Wirenfelt Klausen et al., “(e
Danish national multiple myeloma registry,” Clinical Epide-
miology, vol. 8, pp. 583–587, 2016.
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